CAR T-Cell Therapy for Large B-Cell Lymphoma

MARITZA C. ALENCAR

首页> 外文期刊>Journal of the advanced practitioner in oncology >CAR T-Cell Therapy for Large B-Cell Lymphoma

【24h】

CAR T-Cell Therapy for Large B-Cell Lymphoma

机译：大型B细胞淋巴瘤的汽车T细胞疗法

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Chimeric antigen receptor (CAR) T-cell therapy represents an exciting innovation in the treatment of cancer. With the approval of two revolutionary anti-CD19 CAR T-cell therapies (axicabtagene ciloleu-cel [Yescarta] and tisagenlecleucel [Kymriah]) for relapsed/refractory large B-cell lymphoma, health-care providers must consider how to prepare for the future of cancer care. While these therapies have been shown to provide clinical benefit to many patients, they are associated with a range of adverse events (AEs) that will need to be identified, assessed, and managed. Widespread education of health-care providers, patients, and caregivers will also be essential to ensure the success of this novel treatment. This supplement aims to provide practical information to the advanced practitioner on a number of considerations relating to the implementation and expansion of CAR T-cell therapy, including CAR T-cell biology and mechanism of action, how to identify, grade, and manage treatment-related AEs, as well as best practices for educating patients and caregivers about this type of therapy.

机译：嵌合抗原受体（汽车）T细胞疗法代表癌症治疗的激动创新。通过批准两种革命性的抗CD19汽车T细胞疗法（AxicabTageneCiloleu-cel [Yescarta]和Tisagenlecleucel [Kymriah]）进行复发/难治性大B细胞淋巴瘤，医疗保健提供者必须考虑如何为未来做好准备癌症护理。虽然已经显示这些疗法为许多患者提供临床益处，但它们与需要识别，评估和管理的一系列不良事件（AES）相关。卫生保健提供者，患者和护理人员的广泛教育对于确保这部小型治疗的成功也至关重要。该补充旨在向先进的从业者提供有关涉及汽车T细胞疗法的若干考虑因素的现实信息，包括汽车T细胞生物学和行动机制，如何识别，等级和管理治疗 - 相关AES，以及教育患者和护理人员关于这种疗法的最佳实践。

著录项

来源
《Journal of the advanced practitioner in oncology》 |2019年第3期|共5页
作者
MARITZA C. ALENCAR;
展开▼
作者单位

UM Sylvester Comprehensive Cancer Center Miami Florid;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. [J] . Bouabdallah R, Mounier N, Guettier C, Journal of Clinical Oncology . 2003,第7期

机译：化疗后，富含T细胞/组织细胞的大B细胞淋巴瘤和经典弥漫性大B细胞淋巴瘤的结果相似：配对对照分析。
2. CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome [J] . Liting Chen, Bin Xu, Xiaolu Long, Journal for ImmunoTherapy of Cancer . 2020,第1期

机译：在Li-Fraumeni综合征的语境中，汽车T细胞治疗复发/难治性急性B细胞淋巴细胞淋巴瘤患者
3. Long-term outcomes of Sleeping Beauty generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas [J] . Srour S. A., Singh H., McCarty J., Blood: The Journal of the American Society of Hematology . 2020,第11期

机译：睡美的长期结果为复发 - 难治性B细胞淋巴瘤产生了CD19特异性汽车T细胞疗法
4. Prolonged Remission and Survival in Canine B-Cell Lymphoma After Chemotherapy and Low-Dose Rate Half-Body Radiotherapy [C] . American College of Veterinary Internal Medicine Forum Conference . 2019

机译：化疗后犬B细胞淋巴瘤的延长缓解和存活和低剂量率半体放射治疗
5. Identification of oncogenes in human B-cell and murine T-cell lymphomas. [D] . Kim, Rachel. 2002

机译：人B细胞和鼠T细胞淋巴瘤中致癌基因的鉴定。
6. Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role? [O] . Omran Saifi, Mohamed A. Kharfan-Dabaja, Youssef H. Zeidan, 2020

机译：质子疗法作为汽车T细胞治疗的桥接治疗用于复发和难治性大B细胞淋巴瘤：有角色吗？
7. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-Cell Non-Hodgkin’s lymphoma1,2 1Expert panel members and authors of the review are: Theresa Hahn, PhD, Roswell Park Cancer Institute, Buffalo, NY; Steven N. Wolff, MD, Vanderbilt University, Nashville, TN, Myron Czuczman, MD, Roswell Park Cancer Institute, Buffalo, NY; Richard I. Fisher, MD, Cardinal Bernardin Cancer Center, Loyola University, Chicago, IL; Hillard M. Lazarus, MD, Comprehensive Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH; Philip L. McCarthy, MD, Roswell Park Cancer Institute, Buffalo, NY; Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE; Lisa Warren, Cure for Lymphoma Foundation, New York, NY; and Richard Watt, MD, United Resource Networks, Minneapolis, MN. 2Reference: Hahn T, Wolff SN, Czuczman M, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin’s lymphoma: an evidence-based review. Biol Blood Marrow Transplant. 2001;7:308–331. [O] . 2003

机译：造血干细胞移植的细胞毒性治疗在治疗弥漫性大细胞B细胞非霍奇金淋巴瘤1,2中的作用1，专家小组成员和评价的作者是：纽约州布法罗罗斯威尔公园癌症研究所的特蕾莎·哈恩博士；田纳西州纳什维尔范德比尔特大学医学博士斯蒂芬·沃尔夫（Steven N. Wolff），纽约州布法罗罗斯维尔公园癌症研究所医学博士迈伦·库兹曼（Myron Czuczman）；理查德·费舍尔（Richard I. Fisher）医学博士，伊利诺伊州芝加哥洛约拉大学贝纳尔丁枢机主教癌症中心；俄亥俄州克利夫兰凯斯西储大学克利夫兰大学医院综合癌症中心医学博士Hillard M. Lazarus；纽约州布法罗罗斯韦尔公园癌症研究所医学博士Philip L.内布拉斯加州奥马哈市内布拉斯加大学医学中心医学博士Julie Vose；丽莎·沃伦（Lisa Warren），纽约州纽约市淋巴瘤基金会的治疗；和明尼苏达州明尼阿波利斯市联合资源网络公司的医学博士Richard Watt。 2参考文献：Hahn T，Wolff SN，Czuczman M等。一项基于证据的综述：造血干细胞移植的细胞毒性治疗在弥漫性大细胞B细胞非霍奇金淋巴瘤治疗中的作用。 Biol骨髓移植。 2001; 7：308-331。

CAR T-Cell Therapy for Large B-Cell Lymphoma

摘要

著录项

相似文献

相关主题

期刊订阅